Sterinova

Focused on ready-to-use sterile injectable pharmaceuticals, Sterinova develops, manufactures, and distributes medications supplied in prefilled syringes and solution bags. Its current portfolio includes naloxone hydrochloride injection USP in single-dose syringes and sodium heparin injection USP, formulated for subcutaneous administration. Product development considers concentration, total dose, format, and diluent selection, with an emphasis on room-temperature stability. The company positions ready-to-administer formats as an alternative to preparations made from vials or ampoules, standardizing concentrations and doses for use by healthcare professionals in hospitals and community pharmacies.

Operating in Saint-Hyacinthe's biotechnology hub, the company has held a Health Canada facility licence since 2015 for manufacturing sterile injectable pharmaceutical products, including biologics. Its pharmaceutical plant has been inspected by the FDA and manufactures under Canadian Good Manufacturing Practices guidelines. Nearly 100 pharmaceutical industry professionals work across the organization, whose production capacity reaches millions of units annually. The sterile ready-to-administer format is intended to reduce preparation work, support accurate administration, and simplify inventory management through products with extended room-temperature stability. Its naloxone syringe incorporates a passive safety device, while its heparin syringe uses a safety device to prevent needlestick injuries.